Calam J, Gordon D, Peart W S, Taylor S A, Unwin R J
Br J Pharmacol. 1987 Jun;91(2):307-14. doi: 10.1111/j.1476-5381.1987.tb10285.x.
Pentagastrin and cholecystokinin octapeptide (CCK8) were infused i.v. at three different doses in two sets of 4 conscious rabbits following a repeated measurements design (130, 1,300 and 13,000 pmol kg-1 min-1 pentagastrin; 5, 50 and 450 pmol kg-1 min-1 CCK8). In man, two different doses of pentagastrin (13 and 65 pmol kg-1 min-1) were infused in two groups of 6 subjects, and CCK8 (2 pmol kg-1 min-1) in a third group. According to published human postprandial levels, plasma CCK8-like immunoreactivity concentrations were supraphysiological at all doses infused. In the rabbit, pentagastrin produced a dose-related fall in urine flow and free water clearance, but no significant change in systemic and renal haemodynamics, electrolyte excretion and measured plasma constituents; however, in human subjects, pentagastrin increased renal sodium excretion and reduced potassium excretion but did not change glomerular filtration rate. In the rabbit, CCK8 produced a dose-related fall in plasma renin activity, plasma calcium concentration and mean arterial blood pressure; dose-dependent increases in effective renal plasma flow, glomerular filtration rate and renal sodium excretion. In man, changes in sodium and potassium excretion similar to pentagastrin were observed; there were no significant changes in plasma renin activity, plasma calcium concentration, blood pressure, effective renal plasma flow or glomerular filtration rate. The pharmacological renal effects of pentagastrin in conscious water-loaded rabbits resemble vasopressin. In contrast, CCK8's most striking effect was vasodilatation and was unusual in inhibiting rather than stimulating renin release. In man the net changes in urine composition found during infusion of these peptides are similar to those produced by the potassium-sparing diuretics, amiloride and triamterene. However the generally weak renal effects observed, even at pharmacological doses, indicate that these peptides are unlikely to influence renal function under normal physiological conditions.
按照重复测量设计,对两组4只清醒家兔静脉输注五肽胃泌素和八肽胆囊收缩素(CCK8),五肽胃泌素设置三个不同剂量(130、1300和13000 pmol·kg⁻¹·min⁻¹),CCK8也设置三个不同剂量(5、50和450 pmol·kg⁻¹·min⁻¹)。在人体实验中,两组6名受试者静脉输注两种不同剂量的五肽胃泌素(13和65 pmol·kg⁻¹·min⁻¹),第三组6名受试者静脉输注CCK8(2 pmol·kg⁻¹·min⁻¹)。根据已发表的人体餐后水平,所有输注剂量下血浆CCK8样免疫反应性浓度均高于生理水平。在家兔实验中,五肽胃泌素使尿流量和自由水清除率呈剂量依赖性下降,但全身和肾脏血流动力学、电解质排泄及测定的血浆成分无显著变化;然而,在人体受试者中,五肽胃泌素增加肾钠排泄并减少钾排泄,但不改变肾小球滤过率。在家兔实验中,CCK8使血浆肾素活性、血浆钙浓度和平均动脉血压呈剂量依赖性下降;使有效肾血浆流量、肾小球滤过率和肾钠排泄呈剂量依赖性增加。在人体实验中,观察到钠和钾排泄的变化与五肽胃泌素相似;血浆肾素活性、血浆钙浓度、血压、有效肾血浆流量或肾小球滤过率无显著变化。五肽胃泌素对清醒水负荷家兔的药理学肾脏作用类似于血管加压素。相反,CCK8最显著的作用是血管舒张,其抑制而非刺激肾素释放的作用不同寻常。在人体实验中,输注这些肽期间发现的尿液成分净变化与保钾利尿剂阿米洛利和氨苯蝶啶产生的变化相似。然而,即使在药理学剂量下观察到的肾脏作用通常较弱,表明这些肽在正常生理条件下不太可能影响肾功能。